4D Molecular Therapeutics Stock (NASDAQ:FDMT)
Previous Close
$8.67
52W Range
$7.32 - $36.25
50D Avg
$10.17
200D Avg
$20.37
Market Cap
$388.77M
Avg Vol (3M)
$846.25K
Beta
2.80
Div Yield
-
FDMT Company Profile
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
FDMT Performance
Peer Comparison
Ticker | Company |
---|---|
AKRO | Akero Therapeutics, Inc. |
GOSS | Gossamer Bio, Inc. |
CGEM | Cullinan Oncology, Inc. |
RVMD | Revolution Medicines, Inc. Warrant |
MLYS | Mineralys Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
BMEA | Biomea Fusion, Inc. |
STOK | Stoke Therapeutics, Inc. |
IPSC | Century Therapeutics, Inc. |
BDTX | Black Diamond Therapeutics, Inc. |
REPL | Replimune Group, Inc. |
BCEL | Atreca, Inc. |
KRON | Kronos Bio, Inc. |
PASG | Passage Bio, Inc. |
CCCC | C4 Therapeutics, Inc. |
FIXX | Q32 Bio Inc. |
LYRA | Lyra Therapeutics, Inc. |
NVCT | Nuvectis Pharma, Inc. |